Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLTE Belite Bio, Inc.

Pre-Mkt 05-13 07:40:30 EDT

155.54

+3.57

+2.35%

盘前156.00

+0.46+0.30%

05:04 EDT

High157.00	Low150.48	Vol87.20K
Open151.22	D1 Closing151.97	Amplitude4.29%
Mkt Cap6.22B	Tradable Cap3.02B	Total Shares39.97M
T/O13.50M	T/O Rate0.45%	Tradable Shares19.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BLTE","market":"US","secType":"STK","nameCN":"Belite Bio, Inc.","latestPrice":155.54,"timestamp":1778616000000,"preClose":151.97,"halted":0,"volume":87203,"hourTrading":{"tag":"盘前","latestPrice":156,"preClose":155.54,"latestTime":"05:04 EDT","volume":30,"amount":4680,"timestamp":1778663065852,"change":0.46,"changeRate":0.002957,"amplitude":0},"delay":0,"changeRate":0.023491478581298898,"floatShares":19386600,"shares":39965314,"eps":-2.31411,"marketStatus":"Pre-Mkt","change":3.57,"latestTime":"05-13 07:40:30 EDT","open":151.22,"high":157,"low":150.48,"amount":13499088.0023,"amplitude":0.042903,"askPrice":159.21,"askSize":100,"bidPrice":62.52,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.31411,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778679000000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1651204800000,"exchange":"NASDAQ","adjPreClose":155.54,"preHourTrading":{"tag":"盘前","latestPrice":156,"preClose":155.54,"latestTime":"05:04 EDT","volume":30,"amount":4680,"timestamp":1778663065852,"change":0.46,"changeRate":0.002957,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":155.54,"preClose":155.54,"latestTime":"16:18 EDT","volume":327,"amount":50880.78,"timestamp":1778617108090,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8282420717282587},"requestUrl":"/m/hq/s/BLTE","defaultTab":"news","newsList":[{"id":"2634782462","title":"Belite Bio CSO Nathan L. Mata disposes 666 shares worth $102,274.53","url":"https://stock-news.laohu8.com/highlight/detail?id=2634782462","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634782462?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:46","pubTimestamp":1778273190,"startTime":"0","endTime":"0","summary":"Belite Bio reported Chief Scientific Officer Nathan L. Mata sold 666 American depositary shares on May 7, 2026.Sales prices ranged from USD 152.35 to USD 155.29 per share, disclosed on a weighted-average basis.Mata held 0 American depositary shares following the transactions.Transactions were executed under a Rule 10b5-1 trading plan adopted Dec. 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL3bn2KT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CSO Nathan L. Mata disposes 666 shares worth $102,274.53","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633171437","title":"Belite Bio CSO Nathan L. Mata reports disposal of shares worth $153,957.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2633171437","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633171437?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:19","pubTimestamp":1778185148,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares on May 6.Sales priced between USD 151.57 and USD 156 per share.Directly held stake fell to 666 American depositary shares.Transactions executed under a Rule 10b5-1 trading plan adopted Dec. 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL2JK7YG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CSO Nathan L. Mata reports disposal of shares worth $153,957.36","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633929130","title":"Belite Bio CSO Nathan L. Mata sells shares worth $155,707.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2633929130","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633929130?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:17","pubTimestamp":1778012222,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Scientific Officer Nathan L. Mata reported sales of 1,000 American depositary shares on May 4, 2026 at prices ranging from USD 153.50 to USD 157.49.Holdings fell to 2,666 American depositary shares following transactions.Sales were executed under a Rule 10b5-1 trading plan adopted Dec. 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDLbscJcv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CSO Nathan L. Mata sells shares worth $155,707.57","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633965717","title":"Belite Bio CSO Nathan L. Mata disposes of shares worth $156,299.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2633965717","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633965717?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:16","pubTimestamp":1777925782,"startTime":"0","endTime":"0","summary":"Belite Bio reported Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares on May 1, 2026.Sales priced between USD 153.89 and USD 160, leaving Mata with 3,666 American depositary shares.Transaction executed under a Rule 10b5-1 trading plan adopted Dec. 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL22JKNS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CSO Nathan L. Mata disposes of shares worth $156,299.79","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647565","title":"Belite Bio CSO Nathan L. Mata disposes of $157,037 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647565","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647565?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:16","pubTimestamp":1777666572,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares on April 30.Sales were priced at weighted-average prices ranging from USD 155.68 to USD 158.15 per share.Mata held 4,666 American depositary shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL52hJD2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CSO Nathan L. Mata disposes of $157,037 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631290515","title":"Belite Bio CSO Nathan L. Mata disposes of ADSs worth $157,936.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2631290515","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631290515?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:41","pubTimestamp":1777495313,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares on April 28, 2026.Sales were priced at a weighted average range of USD 154.65 to USD 162.14 per share.Mata held 6,666 American depositary shares following transactions.Transactions were executed under a Rule 10b5-1 trading plan adopted on Dec. 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL2px2x0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CSO Nathan L. Mata disposes of ADSs worth $157,936.14","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630310783","title":"Belite Bio CSO Nathan L. Mata disposes of USD 158,424 in shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2630310783","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630310783?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:53","pubTimestamp":1777323193,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Scientific Officer Nathan L. Mata reported sale of 1,000 American depositary shares on April 24, 2026.Sales were executed under a Rule 10b5-1 trading plan adopted Dec. 10, 2025.Disposals were priced at about USD 157.86 to USD 162.53 per share.Mata held 8,666 American depositary shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL4X3HS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Belite Bio CSO Nathan L. Mata disposes of USD 158,424 in shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630396944","title":"Belite Bio to present Phase 3 tinlarebant Stargardt data at Retinal Therapeutics summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396944","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396944?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:02","pubTimestamp":1777291330,"startTime":"0","endTime":"0","summary":"Belite Bio to deliver oral presentation at Retinal Therapeutics Innovation Summit on May 1, 2026, in Denver.Talk scheduled for 10:55-11:10 a.m. MDT, highlighting Phase 3 DRAGON topline data for tinlarebant in Stargardt disease type 1.DRAGON results showed 35.7% reduction in atrophic retinal lesion growth rate versus placebo.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL3x1CPC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4007","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","NDAQ","BLTE","IE00B64PRP62.GBP","BK4112","LU2095319765.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630396158","title":"Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396158","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396158?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:00","pubTimestamp":1777291200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  27, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281569/0/en/Belite-Bio-Announces-Oral-Presentation-at-the-Retinal-Therapeutics-Innovation-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","BK4614","LU1951200564.SGD","LU1861559042.SGD","LU0274383776.USD","LU0081259029.USD","BLTE","LU0889565833.HKD","LU0719512351.SGD","LU1923623000.USD","LU1242518857.USD","BK4539","IE00BMPRXN33.USD","LU1303367103.USD","AMDW","LU0056508442.USD","LU2458330169.SGD","AMYY","BK4532","BK4566","BK4529","AMDU","LU0823434740.USD","LU0127658192.USD","LU1852331112.SGD","BK4211","LU2458330243.SGD","BK4512","BK4139","AMUU","BK4141","LU1880398471.USD","BK4534","LU0979878070.USD","LU0109392836.USD","BK4585","LU2360106780.USD","LU0823434583.USD","LU2098885051.SGD","LU1880398554.USD","BK4573","LU0642271901.SGD","LU1988902786.USD","IE00B5949003.HKD","LU1316542783.SGD","LU2931357623.SGD","DAMD","LU1803068979.SGD","BK4588","LU0823421416.USD","AMDG","BK4612","IE0004445239.USD","LU2250418816.HKD","LU0082616367.USD","IE0009356076.USD","AMDD","LU2089985449.USD","BK4543","LU0823421333.USD","LU1951198990.SGD","LU2264538146.SGD","LU2860962120.EUR","AMDL","LU0198837287.USD","AMDY","BK4605","BK4554","LU1242518931.SGD","LU1861558580.USD","BK4575","LU0390134368.USD","LU2054465674.USD","LU1989764664.SGD","LU2355687059.USD","IE00BMPRXR70.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630278238","title":"Belite Bio CSO Nathan L. Mata disposes of shares worth $165,863","url":"https://stock-news.laohu8.com/highlight/detail?id=2630278238","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630278238?lang=en_us&edition=fundamental","pubTime":"2026-04-25 04:20","pubTimestamp":1777062050,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares on April 23.Sales were executed at weighted average prices ranging from USD 164.47 to USD 169.56 per share.Mata beneficially owned 9,666 American depositary shares following transactions.Disposals were made under Rule 10b5-1 trading plan adopted on Dec. 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL2B1tHw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CSO Nathan L. Mata disposes of shares worth $165,863","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629839540","title":"Belite Bio to Participate in Four Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2629839540","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629839540?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:00","pubTimestamp":1776945600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3279857/0/en/Belite-Bio-to-Participate-in-Four-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1988902786.USD","LU1242518931.SGD","AMYY","AMDU","LU2250418816.HKD","LU0979878070.USD","LU2860962120.EUR","BK4554","LU1064131342.USD","LU1880398554.USD","LU0109392836.USD","BK4512","BK4605","BK4141","BK4543","LU0719512351.SGD","LU2264538146.SGD","LU1803068979.SGD","AMDY","LU1989764664.SGD","LU2355687059.USD","IE00BMPRXR70.SGD","LU0198837287.USD","LU0823434740.USD","AMDG","LU0823421416.USD","LU1861559042.SGD","LU2458330169.SGD","BK4612","BK4614","LU1880398471.USD","LU0642271901.SGD","LU2458330243.SGD","BK4573","BK4529","IE0004445239.USD","LU2054465674.USD","LU1923623000.USD","DAMD","LU2098885051.SGD","AMUU","LU0081259029.USD","BK4534","LU1852331112.SGD","LU0274383776.USD","LU0823434583.USD","BK4532","LU0082616367.USD","BK4585","LU0127658192.USD","LU0390134368.USD","BK4588","IE00BMPRXN33.USD","LU1242518857.USD","LU1861558580.USD","BK4575","LU2360106780.USD","LU2931357623.SGD","LU0056508442.USD","LU0889565833.HKD","IE00B5949003.HKD","LU1316542783.SGD","AMDW","LU1303367103.USD","AMDD","LU2089985449.USD","LU1951200564.SGD","IE0009356076.USD","LU0823421333.USD","BK4007","BK4566","BLTE","LU1951198990.SGD","AMDL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049606","title":"Belite Bio CMO to present at Deutsche Bank ADR virtual investor conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049606","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049606?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:36","pubTimestamp":1776861378,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Medical Officer Hendrick Scholl scheduled to present at Deutsche Bank ADR Virtual Investor Conference on April 28, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL10fdNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4007","IE00BN0W2T93.GBP","BLTE","BK4112","SG9999014013.SGD","IE00BN0W2W23.USD","BK4585","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629046176","title":"Belite Bio Price Target Maintained With a $200.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2629046176","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629046176?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:16","pubTimestamp":1776860160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLTE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 08:16 ET (12:16 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629065894","title":"Belite Bio CSO Nathan L. Mata disposes of shares worth $163,995.76","url":"https://stock-news.laohu8.com/highlight/detail?id=2629065894","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629065894?lang=en_us&edition=fundamental","pubTime":"2026-04-22 05:29","pubTimestamp":1776806972,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares on April 20.Sales were reported at weighted average prices ranging from USD 162.76 to USD 168.35 per share.Mata held 12,666 American depositary shares following the transactions.Transactions were executed under a Rule 10b5-1 trading plan adopted on Dec. 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL7sVvdT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CSO Nathan L. Mata disposes of shares worth $163,995.76","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629063583","title":"Belite Bio Starts Rolling Submission of New Drug Application for Eye Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2629063583","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629063583?lang=en_us&edition=fundamental","pubTime":"2026-04-22 05:00","pubTimestamp":1776805200,"startTime":"0","endTime":"0","summary":"Belite Bio started rolling submission of a New Drug Application to the Food and Drug Administration for its treatment of a rare retinal disorder.The company on Tuesday said it expects to complete the submission in the second quarter. The NDA is for the company's drug tinlarebant, which is designed to treat Stargardt disease type 1, an inherited retinal disorder caused by genetic mutations that often results in legal blindness.The company has completed a Phase 3 trial in adolescent STGD1 subjects. Tinlarebant was previously granted Breakthrough Therapy Designation by the FDA, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629105043","title":"Belite Bio initiates rolling submission of NDA to U.S FDA for tinlarebant","url":"https://stock-news.laohu8.com/highlight/detail?id=2629105043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629105043?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:09","pubTimestamp":1776802149,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) announced that it has initiated a rolling submission of a New Drug Application, NDA, to the U.S. Food and Drug Administration, FD...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/belite-bio-initiates-rolling-submission-of-nda-to-u-s-fda-for-tinlarebant-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/belite-bio-initiates-rolling-submission-of-nda-to-u-s-fda-for-tinlarebant-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4007","BK4588","BLTE","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629057257","title":"Belite Bio starts FDA rolling NDA submission for tinlarebant in Stargardt disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2629057257","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629057257?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:00","pubTimestamp":1776801623,"startTime":"0","endTime":"0","summary":"Belite Bio initiated a rolling NDA submission to FDA for tinlarebant to treat Stargardt disease type 1.Rolling filing proceeds under FDA Breakthrough Therapy Designation.Completion of NDA submission targeted for Q2 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL8Lh0X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","SG9999014013.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","BK4588","IE00BKPKM429.USD","IE00BN0W2W23.USD","BLTE","IE00BGHQF748.EUR","LU2210150020.SGD","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","NDAQ","LU2095319765.USD","LU2210149790.SGD","BK4007","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629105761","title":"Belite Bio Inc - Expects to Complete Nda Rolling Submission in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629105761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629105761?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:00","pubTimestamp":1776801600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nTUA3L8YTR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629057666","title":"Belite Bio Inc - Tinlarebant Granted Breakthrough Therapy Designation by FDA for Stargardt Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2629057666","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629057666?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:00","pubTimestamp":1776801600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nTUA3L8YTR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629030775","title":"Belite Bio CSO Nathan L. Mata disposes of shares worth $159,910","url":"https://stock-news.laohu8.com/highlight/detail?id=2629030775","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629030775?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:16","pubTimestamp":1776716172,"startTime":"0","endTime":"0","summary":"Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares on April 16, 2026.Sales prices ranged from USD 158.28 to USD 164.12 per share.Mata held 14,666 American depositary shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLbhCTg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Belite Bio CSO Nathan L. Mata disposes of shares worth $159,910","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://investors.belitebio.com;belitebio.com","stockEarnings":[{"period":"1week","weight":0.0075},{"period":"1month","weight":-0.0997},{"period":"3month","weight":-0.1115},{"period":"6month","weight":0.3837},{"period":"1year","weight":1.5091},{"period":"ytd","weight":-0.0276}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0864},{"period":"3month","weight":0.0668},{"period":"6month","weight":0.0984},{"period":"1year","weight":0.2662},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.020711},{"month":2,"riseRate":0.75,"avgChangeRate":0.070972},{"month":3,"riseRate":0.25,"avgChangeRate":-0.067883},{"month":4,"riseRate":0.25,"avgChangeRate":-0.011914},{"month":5,"riseRate":0.6,"avgChangeRate":0.047156},{"month":6,"riseRate":0.25,"avgChangeRate":0.187208},{"month":7,"riseRate":1,"avgChangeRate":0.228556},{"month":8,"riseRate":0.25,"avgChangeRate":0.09699},{"month":9,"riseRate":0.5,"avgChangeRate":0.027284},{"month":10,"riseRate":0.75,"avgChangeRate":0.224047},{"month":11,"riseRate":0.75,"avgChangeRate":0.12408},{"month":12,"riseRate":0.5,"avgChangeRate":0.042173}],"exchange":"NASDAQ","name":"Belite Bio, Inc.","nameEN":"Belite Bio, Inc.","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Belite Bio, Inc.,BLTE,Belite Bio, Inc.股票,Belite Bio, Inc.股票老虎,Belite Bio, Inc.股票老虎国际,Belite Bio, Inc.行情,Belite Bio, Inc.股票行情,Belite Bio, Inc.股价,Belite Bio, Inc.股市,Belite Bio, Inc.股票价格,Belite Bio, Inc.股票交易,Belite Bio, Inc.股票购买,Belite Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction